This finding is interesting and important considering that inhibition of APC/C activation by APN and proTAME seems to involve distinct molecular mechanisms and because the combination of cell cycle-targeted therapies may be key to enhance a therapeutic response in breast, cervical and ovarian cancer cells, which is an important aspect that we will address in future investigations. Here, ANPEP is linked to ovarian cancer.